Immunology

  1. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays

    1. Mei San Tang
    2. James Brett Case
    3. Caroline E Franks
    4. Rita E Chen
    5. Neil W Anderson
    6. Jeffrey P Henderson
    7. Michael S Diamond
    8. Ann M Gronowski
    9. Christopher W Farnsworth

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

    1. Flavia Chiuppesi
    2. Marcela d’Alincourt Salazar
    3. Heidi Contreras
    4. Vu H Nguyen
    5. Joy Martinez
    6. Soojin Park
    7. Jenny Nguyen
    8. Mindy Kha
    9. Angelina Iniguez
    10. Qiao Zhou
    11. Teodora Kaltcheva
    12. Roman Levytskyy
    13. Nancy D Ebelt
    14. Tae Hyuk Kang
    15. Xiwei Wu
    16. Thomas Rogers
    17. Edwin R Manuel
    18. Yuriy Shostak
    19. Don J Diamond
    20. Felix Wussow

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

    1. Alan Bénard
    2. Anne Jacobsen
    3. Maximilian Brunner
    4. Christian Krautz
    5. Bettina Klösch
    6. Izabela Swierzy
    7. Elisabeth Naschberger
    8. Malgorzata J. Podolska
    9. Dina Kouhestani
    10. Paul David
    11. Torsten Birkholz
    12. Ixchel Castellanos
    13. Denis Trufa
    14. Horia Sirbu
    15. Marcel Vetter
    16. Andreas E. Kremer
    17. Kai Hildner
    18. Andreas Hecker
    19. Fabian Edinger
    20. Matthias Tenbusch
    21. Petra Mühl-Zürbes
    22. Alexander Steinkasserer
    23. Enrico Richter
    24. Hendrik Streeck
    25. Marc M. Berger
    26. Thorsten Brenner
    27. Markus A. Weigand
    28. Filip K. Swirski
    29. Georg Schett
    30. Robert Grützmann
    31. Georg F. Weber

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis

    1. Onyeka S. Chukwudozie
    2. Rebecca C. Chukwuanukwu
    3. Onyekachi O. Iroanya
    4. Daniel M. Eze
    5. Vincent C. Duru
    6. Temiloluwa O. Dele-Alimi
    7. Busuyi D. Kehinde
    8. Taiwo T. Bankole
    9. Perpetua C. Obi
    10. Elizabeth U. Okinedo

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Early data on the performance of a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow immunoassay device compared with a nucleocapsid-only device

    1. Christian Linares
    2. Felicity Ryan
    3. Hannah Lowe
    4. Samuel Moses

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses

    1. Ulrik Stervbo
    2. Sven Rahmann
    3. Toralf Roch
    4. Timm H. Westhof
    5. Nina Babel

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies

    1. Priyamvada Acharya
    2. Wilton Williams
    3. Rory Henderson
    4. Katarzyna Janowska
    5. Kartik Manne
    6. Robert Parks
    7. Margaret Deyton
    8. Jordan Sprenz
    9. Victoria Stalls
    10. Megan Kopp
    11. Katayoun Mansouri
    12. Robert J Edwards
    13. R. Ryan Meyerhoff
    14. Thomas Oguin
    15. Gregory Sempowski
    16. Kevin Saunders
    17. Barton F. Haynes

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity

    1. Ganna Petruk
    2. Manoj Puthia
    3. Jitka Petrlova
    4. Firdaus Samsudin
    5. Ann-Charlotte Strömdahl
    6. Samuel Cerps
    7. Lena Uller
    8. Sven Kjellström
    9. Peter J Bond
    10. and Artur Schmidtchen

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

    1. Nanda Kishore Routhu
    2. Sailaja Gangadhara
    3. Narayanaiah Cheedarla
    4. Ayalnesh Shiferaw
    5. Sheikh Abdul Rahman
    6. Anusmita Sahoo
    7. Pei-Yong Shi
    8. Vineet D. Menachery
    9. Katharine Floyd
    10. Stephanie Fischinger
    11. Caroline Atyeo
    12. Galit Alter
    13. Mehul S. Suthar
    14. Rama Rao Amara

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

    1. Tongqing Zhou
    2. I-Ting Teng
    3. Adam S. Olia
    4. Gabriele Cerutti
    5. Jason Gorman
    6. Alexandra Nazzari
    7. Wei Shi
    8. Yaroslav Tsybovsky
    9. Lingshu Wang
    10. Shuishu Wang
    11. Baoshan Zhang
    12. Yi Zhang
    13. Phinikoula S. Katsamba
    14. Yuliya Petrova
    15. Bailey B. Banach
    16. Ahmed S. Fahad
    17. Lihong Liu
    18. Sheila N. Lopez Acevedo
    19. Bharat Madan
    20. Matheus Oliveira de Souza
    21. Xiaoli Pan
    22. Pengfei Wang
    23. Jacy R. Wolfe
    24. Michael Yin
    25. David D. Ho
    26. Emily Phung
    27. Anthony DiPiazza
    28. Lauren A. Chang
    29. Olubukola M. Abiona
    30. Kizzmekia S. Corbett
    31. Brandon J. DeKosky
    32. Barney S. Graham
    33. John R. Mascola
    34. John Misasi
    35. Tracy Ruckwardt
    36. Nancy J. Sullivan
    37. Lawrence Shapiro
    38. Peter D. Kwong

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 22 of 161 Next